We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+2.27%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$7.33B
AUM Growth
+$1.08B
Cap. Flow
+$1.18B
Cap. Flow %
16.06%
Top 10 Hldgs %
55.65%
Holding
321
New
63
Increased
80
Reduced
61
Closed
90

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$101M
2
ICLR icon
Icon
ICLR
+$97.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$87.9M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$82.5M
5
GSK icon
GSK
GSK
+$66.7M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$40.5M
2
PTCT icon
PTC Therapeutics
PTCT
+$36.7M
3
SHAK icon
Shake Shack
SHAK
+$32.9M
4
INCY icon
Incyte
INCY
+$30.5M
5
CYTK icon
Cytokinetics
CYTK
+$30.4M

Sector Composition

Rank Sector Weight
1 Healthcare 39.34%
2 Consumer Discretionary 6.39%
3 Consumer Staples 5.37%
4 Technology 5.27%
5 Communication Services 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HSCSW icon
226
HeartSciences Inc Warrant
HSCSW
$71K
$106 ﹤0.01%
+3,529
New +$133
CINGW icon
227
Cingulate Inc Warrants
CINGW
$33.2K
$88 ﹤0.01%
+1,708
New +$86
EDBLW
228
Edible Garden AG Warrant
EDBLW
$65.4K
$47 ﹤0.01%
+1,334
New +$29
AREBW
229
DELISTED
American Rebel Holdings Warrants
AREBW
$27 ﹤0.01%
+21
New +$22
DRMAW icon
230
Dermata Therapeutics Warrant
DRMAW
$12.4K
$14 ﹤0.01%
+1,354
New +$14
TCBPW
231
DELISTED
TC BioPharm (Holdings) plc Warrants
TCBPW
$2 ﹤0.01%
+188
New +$3
AAL icon
232
American Airlines Group
AAL
$10.6B
– –
-16,407
Closed -$184K
ABNB icon
233
Airbnb
ABNB
$106B
– –
-2,165
Closed -$275K
ALC icon
234
Alcon
ALC
$35B
– –
-70,740
Closed -$7.08M
ALGS icon
235
Aligos Therapeutics
ALGS
$34.6M
– –
-315,095
Closed -$2.73M
ALKS icon
236
Alkermes
ALKS
$8.25B
– –
-1,448,654
Closed -$40.5M
ANF icon
237
Abercrombie & Fitch
ANF
$5B
– –
-2,640
Closed -$369K
APCX
238
DELISTED
AppTech Payments
APCX
– –
-188,000
Closed -$112K
BCLI
239
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
– –
-459,844
Closed -$1.59M
BKNG icon
240
Booking.com
BKNG
$161B
– –
-2,525
Closed -$425K
BKYI
241
BIO-key International
BKYI
$4.38M
– –
-25,000
Closed -$240K
BNTC icon
242
Benitec Biopharma
BNTC
$468M
– –
-60,000
Closed -$551K
BSX icon
243
Boston Scientific
BSX
$71.5B
– –
-56,855
Closed -$4.76M
CANF
244
Can-Fite BioPharma American Depositary Shares
CANF
$7.37M
– –
-32,500
Closed -$1.31M
CAVA icon
245
CAVA Group
CAVA
$7.27B
– –
-1,624
Closed -$201K
CHTR icon
246
Charter Communications
CHTR
$18.2B
– –
-1,174
Closed -$380K
CLNN icon
247
Clene
CLNN
$67.5M
– –
-682,374
Closed -$3.13M
CLX icon
248
Clorox
CLX
$12.7B
– –
-2,295
Closed -$374K
CMCSA icon
249
Comcast
CMCSA
$90B
– –
-4,920
Closed -$206K
CNK icon
250
Cinemark Holdings
CNK
$4.32B
– –
-19,740
Closed -$550K
8 9
10
11 12

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return
PI
PGGM Investments Zeist, Netherlands $5.7B AUM 17.05% 1-Year Est. Return

Armistice Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Armistice Capital held 321 positions worth $7.33B, up 17% from $6.25B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Armistice Capital deployed $1.18B of net new capital in Q4 2024, opening 63 new positions and adding to 80 existing holdings. Its largest new stake was Exact Sciences: 1,617,000 shares worth $90.9M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 42% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was PTC Therapeutics, an estimated $36.7M trimmed.

  • Armistice Capital's largest Q4 2024 buy was Exact Sciences: 1,617,000 shares worth $90.9M.
  • Armistice Capital added most to Neurocrine Biosciences in Q4 2024, an estimated $87.9M increase.
  • Armistice Capital's biggest Q4 2024 reduction was PTC Therapeutics, cutting an estimated $36.7M.
  • Armistice Capital fully exited Alkermes in Q4 2024, selling an estimated $40.5M.
  • Armistice Capital's ten largest holdings make up 56% of its $7.33B portfolio in Q4 2024.
  • Armistice Capital opened 63 new positions and closed 90 in Q4 2024.
  • Armistice Capital's portfolio value rose 17% quarter-over-quarter to $7.33B.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.